Glenmark Life Sciences Limited (GLS.NS)

Growth (Per Share)

Revenue 5Y—
Revenue 3Y—
Earnings 5Y—
Earnings 3Y—
Dividend 5Y—
Dividend 3Y—

Capital Efficiency

ROIC—
ROE—
ROA—
ROTA—

Capital Structure

Market Cap67.18B
EV67.18B
Cash—
Current Ratio—
Debt/Equity—
Net Debt/EBITDA—
Show More

Select a metric from the list below to chart it

Income Statement
Mar '19
Mar '20
Mar '21
Mar '22
Mar '23
Revenue
169.8
185.8
227.9
256.6
261.2
Revenue % Chg.
—
9.4%
22.6%
12.6%
1.8%
Cost of Revenue
75.7
83.5
109.5
126.1
122.6
Gross Profit
94.1
102.4
118.4
130.6
138.7
Gross Profit Margin
55.4%
55.1%
52.0%
50.9%
53.1%
R&D Expenses
0.0
—
0.0
—
—
Selling, General, & Admin Expenses
4.3
4.0
5.0
4.8
—
Other Expenses
40.3
44.7
45.5
55.8
66.1
Operating Income
49.5
55.1
67.6
71.8
76.0
Operating Income Margin
29.1%
29.6%
29.7%
28.0%
29.1%
Total Other Income/Expenses Net
-0.7
-4.2
-10.7
-3.5
-0.1
Income Before Tax
48.8
50.9
56.9
68.3
76.0
Income Before Tax Margin
28.7%
27.4%
25.0%
26.6%
29.1%
Income Tax Expense
13.4
13.1
14.4
17.7
19.5
Net Income
35.4
37.8
42.5
50.6
56.4
Net Income Margin
20.8%
20.4%
18.6%
19.7%
21.6%
Weighted Avg. Shares Out
122.5
122.5
122.5
117.5
—
EPS
0.3
0.3
0.3
0.4
—
EPS % Chg.
—
7.0%
12.3%
24.2%
—
Weighted Avg. Shares Out Dil
122.5
122.5
122.5
117.5
—
EPS Diluted
0.3
0.3
0.3
0.4
—
Interest Income
—
0.0
0.1
0.8
—
Interest Expense
0.1
4.1
10.6
3.4
0.1
EBIT
48.7
46.9
46.4
65.7
75.9
EBIT Margin
28.7%
25.2%
20.4%
25.6%
29.1%
Depreciation & Amortization
2.3
3.5
4.0
4.6
5.1
EBITDA
51.1
50.4
50.4
70.3
81.0
EBITDA Margin
30.1%
27.1%
22.1%
27.4%
31.0%